Damages Awarded In J&J's DePuy Hip Implant Case
By GREG RISLING
LOS ANGELES (AP) â¿¿ A jury Friday awarded $8.3 million to a former prison guard who accused Johnson & Johnson's DePuy Orthopaedics subsidiary of knowingly marketing a faulty hip implant that was later recalled.
Jurors found that the ASR XL implant was defectively designed and caused metal poisoning and other health problems suffered by Loren Kransky after he underwent surgery in 2007.
However, the panel rejected the 65-year-old's claim that DePuy failed to adequately warn of the risks associated with the implant, and it didn't find the company acted with malice, prohibiting Kransky from collecting any punitive damages.The fraud and negligence suit is the first of nearly 11,000 similar cases involving an all-metal ball-and-socket hip joint that was pulled from the market two years ago to reach trial in the United States. Others like Kransky claim the implants have left them with crippling injuries or in need of other replacement surgeries. Johnson & Johnson has set aside about $1 billion to cover costs of the recall and lawsuits. Plaintiff's attorney Doug Saeltzer said the verdict bodes well for the other cases. "The message is that these cases are valid, that the injuries are real and severe, and Johnson & Johnson and DePuy have to pay significant money for their mistakes," Saeltzer said. Loire Gawreluk, a DePuy spokeswoman, said the Warsaw, Ind., company plans to appeal the verdict. "We believe ASR XL was properly designed, and that DePuy's actions concerning the product were appropriate and responsible," she said. During the trial, Kransky's lawyers told jurors that black pieces of metal flaked off the implant and caused a type of poisoning that could have killed him if the material had not been removed. Brian Panish, one of Kransky's attorneys, said during closing arguments that the company "knew this hip was defective long before Mr. Kransky got it," the Los Angeles Times reported.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV